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Crystal Structure of -Arrestin at 1.9 A˚:
Possible Mechanism of Receptor Binding
and Membrane Translocation
encodes 1000 GPCRs and numerous G protein sub-
units. GPCR-mediated signaling is the most common
way for cells to receive chemical signals from the ex-
tracellular environment. Arrestins play a central role in
controlling the amplitude and duration of the GPCR sig-
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Yale University naling. Arrestins bind exclusively to activated and phos-
phorylated GPCRs. They terminate the primary signalNew Haven, Connecticut 06520
2 Ralph and Muriel Roberts Laboratory transduction event by preventing further interaction of
G proteins with the receptor. The arrestin family consistsfor Vision Science
Sun Health Research Institute of visual arrestin (v-arrestin), cone arrestin, -arrestin
(synonyms, -arrestin 1 and arrestin-2), and -arrestin2Sun City, Arizona 85372
3 Howard Hughes Medical Institute (synonym, arrestin3). V- and cone arrestins are exclu-
sively expressed in rod and cone photoreceptors, re-
spectively. They are highly specialized to bind specifi-
cally to rhodopsin, or cone cell pigments. The structureSummary
of v-arrestin was reported [1, 2]. The two closely related
-arrestins are ubiquitously expressed and are respon-Background: Arrestins are responsible for the desensi-
sible for the termination of the primary signaling eventtization of many sequence-divergent G protein-coupled
for most, if not all, class I GPCRs. They also interact withreceptors. They compete with G proteins for binding to
clathrin and the AP2 adaptor protein to trigger receptoractivated phosphorylated receptors, initiate receptor inter-
sequestration into clathrin-coated pits [3–5]. -arrestinnalization, and activate additional signaling pathways.
also interacts with the N-ethylmaleimide-sensitive fu-
sion protein, linking receptor sequestration and vesicu-Results: In order to understand the structural basis for
lar transport [6]. Furthermore, it was shown that -arres-receptor binding and arrestin’s function as an adaptor
tin binds to the SH3 and catalytic domains of c-Srcmolecule, we determined the X-ray crystal structure of
kinase in a receptor activation-dependent manner [7,two truncated forms of bovine -arrestin in its cytosolic
8]. This interaction provides a crucial link between theinactive state to 1.9 A˚. Mutational analysis and chimera
GPCR pathway and the mitogen-activated protein ki-studies identify the regions in -arrestin responsible for
nase (MAPK) pathways. In addition, -arrestin is in-receptor binding specificity. -arrestin demonstrates
volved in regulation of mitogenic signaling and endocy-high structural homology with the previously solved vi-
tosis of the IGF-1 receptor, a non-GPCR [9].sual arrestin. All key structural elements responsible for
-arrestin knockout (/) mice display altered car-arrestin’s mechanism of activation are conserved.
diac responsiveness to -adrenergic receptor stimula-
tion [10]. -arrestin2 knockout (/) mice demonstrateConclusions: Based on structural analysis and muta-
enhanced morphine analgesia [11]. Neither knockoutgenesis data, we propose a previously unappreciated
displays an apparent abnormality, implying that there ispart in -arrestin’s mode of action by which a cationic
functional redundancy between these two proteins. Thisamphipathic helix may function as a reversible mem-
hypothesis is supported by the fact that the two genesbrane anchor. This novel activation mechanism would
show extensive tissue expression overlap [12] and func-facilitate the formation of a high-affinity complex be-
tional redundancy in that they bind many receptors withtween -arrestin and an activated receptor regardless
comparable affinity [13]. However, a double knockoutof its specific subtype. Like the interaction between
of both -arrestins is embryonic lethal [14]. Similarly,-arrestin’s polar core and the phosphorylated receptor,
knockouts (/) of kurtz, a -arrestin analog in Dro-such a general activation mechanism would contribute to
sophila, display a broad lethal phase during embryogen--arrestin’s versatility as a regulator of many receptors.
esis [15].
Despite common molecular architecture and a fewIntroduction
highly conserved residues scattered within the trans-
membrane segments, the sequence homology amongSignal transduction pathways involving G protein-cou-
all GPCRs is very low. The structural basis of -arrestin’spled receptors (GPCRs) control many vital processes of
ability to interact with hundreds of different receptorslife, such as perception, hormone and neurotransmitter
is unknown.action, angiogenesis, and behavior. The human genome
Here we report the expression, purification, and crys-
tallization of bovine -arrestin in two truncated forms:
-arrestin 1–393 and 1–382, lacking the last 25 and 36
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-arrestin is similar to that of visual arrestin [1]: an elon-6 Present address: Millennium Pharmaceuticals, Inc., 75 Sidney
Street, Cambridge, Massachusetts 02139.
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Table 1. Data Collection Statistics
Molecule -arrestin 1–393 -arrestin 1–393 -arrestin 1–382
Cell parameters P21 P3221 P21
a  62.4 A˚, b  73.7 A˚, c  115.8 A˚, a  b  77.8 A˚, c  157.1 A˚ a  62.4 A˚, b  73.3 A˚, c  115.3 A˚,
    90,   98.7     90,   120     90,   98
Collection Strategy SAD High resolutiona Native SAD Native
Resolution (A˚) 34–2.1 31–1.9 35–1.96 34–2.2 31–2.0
Wavelength (A˚) 0.979 1.1 1.105 0.9785 1.1
Observations/Unique 387,810/58,960 238,590/68,946 158,905/49,309 267,488/27,920 226,069/68,102
Rsym (%)b,c 8.0 (46.2) 5.0 (46.6) 4.7 (46.8) 4.6 (45.6) 5.9 (48.2)
Rmeas (%)b,d 8.7 (50.9) 5.9 (58.8) 5.6 (58.3) 4.8 (52.9) 7.0 (59.0)
Redundancyb 6.6 (5.2) 3.5 (2.2) 3.2 (1.5) 9.6 (3.8) 3.3 (2.5)
Completeness (%)b 96.9 (88.2) 84.5 (35.4) 65.8 (3.6) 94.7 (79.2) 95.1 (91)
I/b,e 5.6 (1.8) 7.3 (1.3) 7.5 (1.1) 10.4 (1.5) 5.8 (1.4)
HA-Refinement SIRAS SAD
Resolution (A˚) 34–1.9 34–2.2
Riso (%)f 8.7 12.9 —
f /f ″ 20.5/9.7 4.05/3.05
Phasing powercen/isog 0.39 — 0.22 —
Phasing poweracen/isog 0.56 — 0.2 —
Phasing poweracen/anog 1.1 — — 1.3
Figures of merith 0.14 (centrics) 0.07 (centrics) 0.25 (acentrics)
0.2 (acentrics)
a Reference data set in heavy-atom refinement.


































, where nh is the redundancy.
e Based on unmerged data.
f Riso  	|FPH  FP|/	FP, where FP and FPH are the native and derivative structure factor amplitudes.
g Phasing power  
rms heavy-atom structure factor/
rms lack of closure
h Figure of merit  weighted mean of the cosine of the deviation from best
gated molecule with a central polar core flanked by of similar trigonal morphology belonging to space group
P3221, with one molecule per asymmetric unit. The limitthe N and C domains and a C tail connecting the two
domains. Structural variations were mostly found in sur- of diffraction was 2.2 A˚. -arrestin 1–393 also yielded
crystals of space group P21, with two molecules perface loops. The crystal structures suggest two possible
mechanisms promoting receptor-arrestin interaction asymmetric unit that diffracted to 1.9 A˚. The structures
of both crystal forms were solved by molecular replace-that are independent of the specific GPCR subtype. One
mechanism is linked to the polar core, where critical salt ment using v-arrestin as the search model and were
refined against external phases obtained from singlebridges keep arrestin in its basal state [1]. An activated
and phosphorylated GPCR would interact with arrestin, wavelength anomalous dispersion (SAD) experiments
to minimize model bias (Figure 1; Table 2). We alsothereby disrupting the polar core and triggering the con-
formational changes required for high-affinity receptor crystallized -arrestin 1–382, which was shown to ex-
hibit phosphorylation-independent receptor bindingbinding. Based on structural and mutagenesis data, we
propose a second general mechanism whereby receptor due to the removal of the key regulatory residues [16].
-arrestin 1–382 exists in solution as a mixture of dimersbinding is triggered and/or enhanced by the membrane
translocation of arrestin’s amphipathic  helix I. and monomers that can be separated by gel-filtration
chromatography. Both dimeric and monomeric -arrestin
1–382 yielded only monoclinic crystals with the sameResults and Discussion
cell dimension as the P21 crystal form of-arrestin 1–393
and diffracted to 2.4 A˚ and 1.9 A˚, respectively. The struc-Structure of -Arrestin
The crystallographic statistics are summarized in Table tures were solved by molecular replacement and were
found to be essentially identical to the search model,1. Large crystals of trigonal morphology were obtained
from wild-type bovine -arrestin but did not diffract be- the P21 form of -arrestin 1–393.
An overlay of -arrestin structures (the P3221 formyond 9 A˚. -arrestin 1–393, lacking the last 25 amino
acids, is biochemically indistinguishable from the wild- and the  and  molecules of the dimer in the P21 form
of -arrestin 1–393 [Figure 2a, gold]) together with twotype arrestin [16]. This truncated form yielded crystals
Structure of -Arrestin
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Figure 1. Ribbon Diagram of -arrestin
The N and C termini are indicated by N and
C, respectively. The color varies from blue to
red as one goes from the N terminus to the
C terminus. Figure generated with MOL-
SCRIPT/RASTER3D [69, 70].
structures of v-arrestin (Figure 2a, magenta) [1] demon- D297 are released as the polar core is perturbed. The
sequence corresponding to the lariat loop 280–310 instrates that the overall structure of -arrestin is very
similar to that of v-arrestin. The loop regions that vary -arrestin was found to be the major epitope for autoim-
mune antibodies found at high levels in the sera of somebetween -arrestin and v-arrestin also vary between
different crystal forms of the same protein, reflecting the multiple sclerosis patients [19]. The equivalent region in
v-arrestin is one of the highly pathogenic epitopes forintrinsic flexibility of those regions rather than inherent
structural differences between the two arrestins. As with the autoimmune disease uveoretinitis [20].
The proline-rich regions 88–96 and 120–124 inv-arrestin [1], the crystal structure of -arrestin repre-
sents its inactive basal state, where the polar core is -arrestins are responsible for binding to the SH3 do-
main of c-Src [7]. SH3 domains mediate binding betweenintact. The unique sequence between residues 357–382
in -arrestins, which contains the clathrin binding site, proteins through hydrophobic interactions via a polypro-
line helix II (PPII) conformation characterized by φ andis disordered in all crystal forms. Interestingly, almost
all of the residues (334–340) absent in a short splice  angles of 78 and 149, respectively [21]. Residues
88–89 do not display a PPII-type conformation. Resi-variant of -arrestin [12, 17] are also disordered.
The polar core, which has been shown to keep dues 119–120 and 123–126 display strong characteris-
tics of a canonical PPII, while the intervening P121 andv-arrestin in its basal conformation [1], is structurally
conserved in -arrestin. The “lariat” loop (Figure 2b, N122 are not in a PPII conformation in the -arrestin
structures. Conceivably, upon arrestin’s transition intoblue, 282–309) is highly conserved among all arrestins and
contains the primary counterion D290 for R169 in the polar the active state and receptor binding, these two amino
acids undergo the necessary conformational changescore. It is a long stretch of amino acids apparently lacking
any secondary structure, yet its tertiary structure is virtually to transform residues 119–126 into a continuous PPII
that is capable of c-Src binding. This may explain whyidentical in v-arrestin and -arrestin . The charge reversal
mutant D296R in v-arrestin (the equivalent of D290R in Src activation by -arrestin depends on receptor bind-
ing. In contrast, the equivalent region in v-arrestin (122–-arrestin) demonstrates phosphorylation-independent
receptor binding [1, 18]. The conserved structure of the 128) does not display any PPII features.
The structural and sequence similarities among all ar-lariat loop implies that its conformation is essential in
stabilizing the basal state of arrestin. The lariat loop is restins suggest that receptor binding mechanisms are sim-
ilar, although details of particular interactions may differ.likely to undergo significant structural changes upon
activation when the constraints imposed on D290 and Thus, mutagenesis results obtained with v-arrestin can be
Table 2. Data Refinement Statistics
Molecule -arrestin 1–393 -arrestin 1–393 -arrestin 1–382
Space group P21 P3221 P21
Number of reflections (work/free) 65,249/5,401a 47,246/5,218 66,013/2,063
Resolution (A˚) 35–1.9 33–2.2 33–2.0
Rwork/Rfree (%)b,c 23.5 (37.9)/26.9 (40.2) 23.9 (35.5)/26.7 (39.2) 25.4 (38.7)/28.0 (38.3)
Mol/ASU 2 1 2
Rms Deviation from Ideality
Bond angles () 1.7 1.6 1.24
Bond length (A˚) 0.011 0.01 0.005
Residues/theoretical 713/786 353/393 651/764
Protein atoms 5,657 2,798 5,154
Water atoms 269 102 283
a Against combined reference structure factors from SHARP.
b Values for the highest resolution shell are given in parentheses.




Full-length -arrestin and the -arrestin 1–393 trunca-
tion mutant both exist as monomers in solution, as as-
sayed by gel-filtration chromatography. In contrast, the
only marginally shorter truncation mutant -arrestin
1–382 exists as a mixture of monomeric and dimeric
species (with a ratio of 4 to 1).
The differences in dimerization properties among vari-
ous constructs of -arrestin are also reflected in oligo-
meric states of the molecules in the crystals. Full-length
-arrestin yields only trigonal crystals with one monomer
per asymmetric unit, whereas -arrestin 1–382 yields
exclusively monoclinic crystals with one dimer per asym-
metric unit. The intermediate -arrestin 1–393 yields
both forms. Most likely, the structure observed in the
trigonal crystal form is that of the solution monomer,
and the structure in the monoclinic crystal form repre-
sents the solution dimer. The two conformations are
very similar with the exception of a few loop regions
(Figure 2a), and both represent the inactive basal state
of the molecule. A dimer of -arrestin 1–393 in the mono-
clinic form is shown in Figure 3a. The dimer of -arrestin
1–382 is essentially identical to that of -arrestin 1–393.
Monomeric and dimeric forms of v-arrestin are at equi-
librium under physiological conditions [25]. It was pro-
posed that the dimer represents an inactive species of
Figure 2. Structural Similarity and B Factor Distribution in Arrestins v-arrestin, which, upon dissociation, yields active mono-
(a) Structural alignment between -arrestin and v-arrestin. A super- mer. This would ensure a low steady-state concentration
imposition of -arrestin 1–393 and v-arrestin structures is shown. of monomeric arrestin and prevent premature quench-
The three -arrestin structures () described in this report are shown
ing of the signal due to an oversupply of arrestin. Inter-in gold; v-arrestin (v)  and  [1] are drawn in purple. Highly flexible
estingly, the deletion of -arrestin’s C tail enhancesregions, which vary within and between both families of proteins, are
dimerization, whereas the equivalent truncation ofindicated by arrows. Figure generated with MOLSCRIPT/RASTER3D
[69, 70]. v-arrestin actually decreases its tendency to dimerize
(b) B factor distribution of -arrestin. Worm diagram of -arrestin, [25]. The dimerization interfaces utilized by the two pro-
P3221 form, along with the B factor encoded in the variable radius. teins are different. V-arrestin employs a head-to-tail ar-
On average, the N domain (purple) displays a higher B factor com-
rangement, whereby the C domain of one molecule inter-pared to the C domain (cyan). -arrestin’s C tail (383–392) is depicted
faces with the N domain of its binding partner (Figurein orange, and the lariat region (280–310) is drawn in dark blue.
3b). In contrast, -arrestin forms a tail-to-tail dimer, withFigure generated in SPOCK/RASTER3D [70].
two C domains interfacing each other (Figure 3a). The
buried surface areas [26] for -arrestin and v-arrestininterpreted in the context of -arrestin. In addition to
dimers are 1400 and 2000 A˚2, respectively. We believetheir ability to bind to a wide range of GPCRs,-arrestins
that the wild-type -arrestin predominantly exists as aare more versatile in downstream effector interactions.
monomer in the cell for two reasons. First, full-lengthThey mediate other cellular processes such as activation of
-arrestin exists as a monomer under physiologicalthe mitogenic pathways through interactions with c-Src [7,
conditions; dimerization is only observed for truncated8] and downstream kinases [14] as well as receptor endo-
proteins. Second, the intracellular concentration ofcytosis through interactions with clathrin and AP2 [3–5].
-arrestin is likely to be much lower than the concentra-Analysis of the temperature-factor distribution of ar-
tion of v-arrestin in rod cells (50–170 M [27, 28]), fa-restins (Figure 2b) shows that the N domain (purple) is
voring the monomeric state. Hence, there is a mechanis-considerably more flexible than the C domain (cyan)
tic difference between v- and -arrestins regardingdespite the higher sequence conservation observed in
activity regulation through self-association. Severalthe N domain. This profile is observed throughout all
lines of evidence indicate that upon receptor binding,structures of -arrestin and v-arrestin (data not shown).
arrestin’s C tail is displaced [16, 22–24]. It is noteworthyThe other two regions with high-temperature factors are
that the removal of the C tail by mutagenesis, mimickingthe lariat region (282–309, blue) and the C tail (383–393,
its displacement during receptor binding, promotesorange). The temperature-factor profile strengthens the
-arrestin dimerization. Displacement of the C tail isnotion that the N domain, the lariat region, and the C
most likely also a necessary step before -arrestin istail undergo substantial conformational rearrangements
able to interact with the2 subunit of the adaptor proteinupon receptor binding, while the more static C domain
AP-2. Recent studies [29] have shown that the con-serves as a structural scaffold. It has been suggested
served residues R393 and R395 in -arrestin (R394 andthat the polar core is disrupted [1] and the C tail dissoci-
R396 in -arrestin2) are essential for this interaction. Inates from arrestin’s surface [16, 22–24] upon binding to
the receptor. -arrestin’s basal state, R393 is an integral part of the
Structure of -Arrestin
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Figure 3. Dimer Interfaces of -Arrestin and
V-Arrestin
(a) Ribbon diagram depicting the dimer inter-
face of -arrestin 1–393 with the view directly
along the two-fold noncrystallographic sym-
metry axis.  and  forms are drawn in blue
and yellow, respectively. The dimer is ar-
ranged in a tail-to-tail configuration.
(b) Dimer interface of v-arrestin arranged in
a head-to-tail configuration.  is drawn in
ochre,  is in green hues.
In both panels the N domain is shown in light
colors and the C domain in darker colors of
the same hue. The buried surface area is
1400 A˚2 for the -arrestin dimer and 2000 A˚2
for the v-arrestin dimer.
polar core and therefore unavailable for binding to AP-2. acid mutation V90S eliminates this difference and per-
mits v-arrestin to bind P-m2 mAchR* with similar affinityIt requires the interaction with the receptor to release
both arginines and translocate the -arrestin-receptor as -arrestin without significant concurrent loss of its
affinity to P-Rh* (Figure 4a). V90 in v-arrestin interactscomplex to clathrin-coated pits through interaction with
AP-2. with V45, V57, V59, and F118 [1], stabilizing the  strand
“sandwich” in the N domain via hydrophobic interac-
tions. In -arrestin, all the potential partners (V41, V53,Defining the Receptor Binding Site
V55, and F115) are conserved, but S86 cannot engageVisual and -arrestins display selectivity toward their
in hydrophobic interactions with them. We believe thatrespective physiological partner receptors. V-arrestin
a relatively rigid N domain, stabilized by V90 and itsbinds to phosphorylated/activated rhodopsin (P-Rh*)
hydrophobic interacting partners, ensures the best fit inwith much higher affinity than to phosphorylated/acti-
the specialized visual arrestins, whereas a substantiallyvated m2 muscarinic cholinergic receptor (P-m2 mAchR*).
more flexible N domain helps nonvisual arrestins to ac--arrestin displays the opposite preference (Figure 4a).
commodate their diverse receptor partners. The reverseSegment-swapping experiments demonstrate that sub-
mutation, S86V in -arrestin, does not have significantstituting residues 50–90 of v-arrestin with the equivalent
impact on its binding to either P-Rh* or P-m2 mAChR*element of -arrestin (46–86) is necessary and sufficient
(Figure 4a).to reverse the binding specificity of v-arrestin (Figure 4a).
The basal states of both arrestins are very similar.A v-arrestin-based chimera with segment 46–86 from -
Their stabilizing elements (the polar core and the 3 ele-arrestin binds P-m2 mAchR* with high affinity, concur-
ment interaction of  helix I,  strand I [residues 6–12],rently losing the affinity for P-Rh*. Other nonoverlapping
and  strand XX [residues 386–390]) are highly con-segments covering the entire N domain do not reverse
served, and analogous mutations in - and v-arrestinsthe arrestin-receptor specificity (data not shown). Pre-
result in similar phenotypes [13, 16]. Despite some differ-sumably, the residues responsible for arrestin-receptor
ences in detailed receptor-arrestin interactions, thisspecificity are directly involved in receptor binding and
suggests that the arrestins’ activation mechanisms areare most likely conserved within each subfamily of ar-
similar, and that structure-function data obtained fromrestins but differ between the families. Residues 46–86
one arrestin class are relevant for the other. Recently,are located on the concave side of the N domain (Figure
Hofmann and coworkers conducted extensive competi-4c, cyan highlights) corresponding to strands V (resi-
tion assays with overlapping peptides covering the en-dues 52–63) and VI (residues 75–87) (Figure 1). Sequence
tire v-arrestin sequence [30]. Although none of the pep-comparison between visual and -arrestin shows that
tides bound directly to the receptor, a few effectivelythe region is highly conserved within each family and
inhibited arrestin binding to P-Rh* with an IC50 of lessdisplays only a few differences between the two families
than 500 M. The ability of a peptide to inhibit arrestin-(Figure 4b). The most pronounced differences are Y47
receptor interaction is a strong indication of the corre-(L51 in v-arrestin), E50 (G54 in v-arrestin), and R65 (Q69
sponding segment’s direct involvement in receptorin v-arrestin), all located on the loops flanking the strictly
binding. However, other segments involved in receptorconserved  strand V (Figure 4c). Another notable differ-
binding may not be revealed in competition bindingence in this region is between S86 in -arrestin 1 and
V90 in v-arrestin (Figure 4b). Remarkably, a single amino assays using isolated peptides. These peptides may
Structure
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Figure 4. Putative Receptor Binding Sites
and Sites Responsible for Receptor Speci-
ficity
(a) Segment 46–86 of -arrestin is necessary
and sufficient to reverse the receptor binding
specificity of v-arrestin.
(b) Sequence alignment of the 46–84 segment
between -arrestin and v-arrestin families.
Two blue arrows signify  strands V and VI.
Residues that are conserved within each fam-
ily but differ between the two are marked with
an asterisk.
(c) Residues 45–86 of -arrestin (highlighted
in cyan), when swapped into v-arrestin, dra-
matically alter v-arrestin’s receptor specific-
ity. Side chains of residues conserved within
each class of arrestin but differ between the
two are shown.
(d) V-arrestin peptides that compete with
v-arrestin for rhodopsin are mapped onto the
-arrestin structure. Colors encode the po-
tency of the competition: yellow, IC50  100
M; orange, 100  IC50  200 M; and red,
200 IC50 400M. Segment 164–176, high-
lighted in green, was shown to be inaccessi-
ble to antibody interaction upon receptor
binding.
be unable to adopt the tertiary structure required for in -arrestin; Figure 4d, green), has also been implicated
in receptor binding since it becomes inaccessible toreceptor binding in the absence of the buttressing effects
of the rest of the protein. We mapped the peptides dis- antibody interaction upon receptor binding [31]. Ac-
cording to mutagenesis studies, several residues in theplaying inhibitory effects onto the structure of -arrestin
(Figure 4d). The most potent peptide 51–70 (44–66 in same region are directly involved in receptor binding
[32, 33]. Interestingly, peptides implicated in receptor-arrestin, yellow) corresponding to  strand V and
flanking loops competes with an IC50 of 25 M. It is binding do not form a contiguous surface (Figure 4d),
suggesting that the receptor/arrestin complex may havealso a part of the 46–86 region responsible for receptor
binding specificity identified by the segment swapping two or more discrete interfaces. This notion is supported
by the finding that multiple receptor elements, cyto-experiments (Figure 4a). Another segment, correspond-
ing to strand X (residues 170–182 in v-arrestin, 164–172 plasmic loops 1, 2, and 3 and the C terminus, participate
Structure of -Arrestin
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Figure 5. Amphipathic Helices and Their Hy-
drophobic Interfaces
The amphipathic helices of (a) -arrestin, (b)
ARF1-GDP, and (c) rhodopsin, respectively.
The helices (purple) are anchored to the ma-
jority of the protein by interactions of hy-
drophobic residues shown in gold. Hydro-
philic residues shown in blue point into the
solvent. Disordered parts of the C-terminal
segment of rhodopsin (c) are shown in gray.
in arrestin binding [34, 35] and that noncontiguous re- helix I (Figure 5a) provide the flexibility necessary for
this structural rearrangement.ceptor residues are involved [36].
Similar activation-induced membrane translocation
via a cationic amphipathic helix has been described forPossible Roles of the Amphipathic  Helix I
ADP-ribosylation factor-1 (ARF1). In the basal state ofin Arrestin Membrane Translocation
ARF1-GDP, an amphipathic N-terminal  helix is boundAll crystal structures of arrestins solved so far represent
in a hydrophobic core similar to  helix I in -arrestinthe basal (inactive) state. Understanding the activation
(Figure 5b) [39]. The conformational changes associatedmechanism requires the determination of the structure
with activation involve substantial structural rearrange-of an arrestin-receptor complex, which remains to be
ments, as revealed by the structure of the active ARF1-crystallized. However, structural analysis combined with
GTP form [40]. As a result of GTP binding, switch 1the interpretation of mutagenesis studies allows us to
transforms from a  hairpin structure to a loop with onepropose a new element of arrestin’s activation mech-
residue moving as much as 16 A˚. Strands 2 and 3anism.
slide 7 A˚ toward the N terminus relative to the invariantResidues 98–108 ( helix I) form a cationic amphi-
part of the molecule and occupy the space that hostspathic helix, where the hydrophobic residues L100,
the  helix in the basal state. The N-terminal  helix hasL104, and L108 are perfectly aligned on the same face
to move away from its original position to accommodateof the helix. This face is flanked on both sides by four
the new active conformation. Biochemical studies usingpositive charges, R99, R103, K106, and K107 (Figure
fluorescence energy transfer showed directly that the5a). The net charge of the helix is3. Such helices often
displaced amphipathic helix translocates and anchorsserve as reversible membrane anchors [37], with the
ARF1 to the cell membrane [41].helix axis lying parallel to the bilayer surface, the hy-
Interestingly, H8 of rhodopsin displays the same cat-drophobic residues inserting into the membrane, and
ionic amphipathic nature. It was shown to lie on thethe positive charges interacting with negatively charged
surface of the bilayer with the helical axis parallel to the
lipid head groups. In the basal state of -arrestin, as
membrane plane, hydrophobic residues (F313, M317,
revealed by the crystal structure, the hydrophobic face
and L321) penetrating into the hydrophobic portion of
of helix I is completely buried in a hydrophobic environ- the bilayer, and the positive charges (K311 and R315)
ment composed of residue V8, the aliphatic chains of at the aqueous-membrane boundary ([42]; Figure 5c).
K10, Y21, V40, V42, I386, and F388 (Figure 5a). Interac- The cationic amphipathic character of the segment is
tions with  strands I and XX further stabilize this posi- well conserved in most of the rhodopsin-family GPCRs
tion of helix I. Receptor binding apparently destabilizes (http://www.gpcr.org/7tm/); therefore, the arrangement
this three element interaction, releasing arrestin’s C tail of H8 is likely to be a common feature of the molecular
[22, 38] and shifting  strand I out of its resting position architecture of GPCRs in addition to the seven trans-
[23]. Destabilization of these interactions by alanine sub- membrane helices. Moreover, the hydrophobic residues
stitutions of hydrophobic residues in either C tail (mutant interact not only with lipids, but also with hydrophobic
3A) or  strand I (mutant N3A) dramatically enhances side chains from transmembrane helices (TMH) 1 and
arrestin binding to all forms of rhodopsin: P-Rh*, un- 7. The phenyl ring of the highly conserved F313 stacks
phosphorylated light-activated (Rh*), and dark-phos- perfectly with the side chain of Y306, a part of a con-
phorylated rhodopsin (P-Rh). In contrast, alanine sub- served motif NPxxY in TMH7, implying the functional
stitution of leucines in  helix I (mutant h3A) only importance of this interaction. We envision that upon
moderately enhances the binding to P-Rh and Rh*. In activation,  helix I of arrestin interacts with the mem-
the context of 3A and N3A mutants, where the 3 element brane in a similar manner as H8 of rhodopsin. The hy-
interaction is already destabilized, mutant h3A demon- drophobic residues thus inserted into the membrane
strated lower binding to all functional forms of rhodop- may also interact with TMH side chains of the receptor
sin. This suggests that hydrophobic residues in  helix close to the cytoplasmic-membrane boundary.
I play an additional binding-enhancing role in the active Reversible membrane anchorage is a common mech-
state of arrestin [23]. We hypothesize that after receptor- anism for cellular redistribution of proteins in response
induced displacement of its partners, the helix flips out to activation. Often it enhances the affinity of a soluble
and inserts itself into the membrane, where it serves as protein for its membrane bound partner [37]. Membrane
an additional membrane anchor and thereby enhances anchors are found in many proteins involved in the
GPCR-mediated signal transduction pathway where thereceptor binding. Extended hinges on both sides of 
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Figure 6. Proposed Receptor Binding Mech-
anism of -Arrestin
The cartoon illustrates the proposed receptor
binding mechanism of arrestins. The N and
C domain are shown in pink and cyan, re-
spectively. The polar core is located at the
interface between the N and C domains and
is represented by charge-charge interactions
(blue-red dots). The C tail is drawn in yellow-
green hues, the N-terminal strand I is in ma-
genta. Positive and negative charges are rep-
resented by blue and red colors; hydrophobic
portions are in yellow. The activated receptor
is depicted in green.
primary event happens at the cell membrane. Proteins the delicate charge balance between partly buried
charged residues and trigger the release of the re-interacting with GPCRs directly, such as G proteins and
receptor kinases, have additional membrane anchors straints, which keep -arrestin in the basal state and
initiates further conformational changes most likely simi-and do not rely solely on receptor binding for their nor-
mal function. The individual G protein subunits are sub- lar to those proposed for v-arrestin [1]. Phosphate-
induced movement of K15 likely forces the  strand Iject to prenylation and acylation [43]. Kinases are preny-
lated and/or bind to the membrane through G out of the position in which it is held by hydrophobic
interactions with  strand XX and  helix I. Having lostinteraction via their PH domains [44]. Regulators of G
proteins (RGS) and kinases are translocated to the mem- their interacting partner,  strand XX and the C tail disso-
ciate away from their current positions and dislodgebrane upon activation via an amphipathic helix [45, 46],
very similar to the scenario proposed for arrestins. In R393 from the polar core [23]. This movement of the C
tail away from the rest of arrestin increases the accessi-the case of recoverin, a Ca2-myristoyl switch [47] is
responsible for membrane binding. Based on structural bility of both the clathrin binding site and AP2 binding
site [29, 52]. As the result of the dissociation of  strandand functional evidence, we believe that arrestin, bind-
ing directly to receptors and organizing many down- XX and the movement of  strand I,  helix I loses
stabilizing hydrophobic interactions provided by bothstream signaling events at the cell membrane, is not
an exception and that  helix I serves as its reversible partners. We hypothesize that the amphipathic  helix
I then swings out from its resting position and interactsmembrane anchor.
with the membrane bilayer to stabilize the receptor-
arrestin complex.Receptor Binding Mechanism
During receptor binding, arrestin undergoes a major
conformational rearrangement as judged by the unusu- Biological Implications
ally high activation barrier of 140 kJ/mol [48, 49]. We
found that the constitutively active mutant -arrestin Comparison of the crystal structure of visual arrestin [1,
2] and the high-resolution structure of -arrestin de-1–382 [16] does not adopt the active conformation in
the absence of the receptor. Apparently, arrestin as- scribed here shows that the overall fold of these mole-
cules is very similar. Moreover, all the key intramolecularsumes its active conformation only in complex with the
receptor. Based on the structures of -arrestin (this interactions that hold arrestins in the basal (inactive)
state are remarkably conserved. These include the polarstudy) and v-arrestin [1] in conjunction with ample bio-
chemical evidence, we propose the following receptor core with its main phosphate sensor (Arg169 in -arrestin),
another positive charge (Arg393), and all three negativebinding mechanism, schematically illustrated in Figure 6.
The inactive conformation is stabilized by an intact charges (Asp290, which serves as the primary counter-
ion for Arg169, as well as Asp26 and Asp297). The threepolar core and a three element hydrophobic interaction
involving  strand I of the N terminus, the last  strand element interaction among  strand I,  strand XX of
the C tail, and  helix I is virtually identical to the interac-XX of the C terminus, and  helix I (Figure 5a). Upon
activation-dependent phosphorylation of GPCRs, an in- tion of the homologous elements in visual arrestin. This
conservation implies that the mechanism of activationcrease in negative electrostatic potential of the receptor
attracts cytosolic arrestin through a patch of strong pos- by phosphorylated agonist-activated receptor is very
similar in these two arrestins. In view of the conservationitive potential (shaded blue in Figure 6), which translo-
cates to the membrane and binds to the GPCR. Multiple of virtually all the residues involved in these interactions
in other cloned arrestin proteins [1], we can further inferphosphorylation at the C terminus of the receptor (red
dots, Figure 6) is necessary for efficient arrestin binding that these mechanisms are conserved throughout the
whole arrestin family. This hypothesis is supported byboth in vitro and in vivo [50, 51]. K15 in v-arrestin’s 
strand I (equivalent to K12 in-arrestin) directly interacts available mutagenesis data [13, 16] as well as by direct
participation of the same parts of visual arrestin andwith receptor-attached phosphates and “guides” them
toward the polar core [23]. Here the phosphates disrupt -arrestin in the interaction with their cognate receptors
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pTrcHisB vector (Invitrogen) between NcoI and HindIII sites, elimi-([30]; Figure 4). Another notable similarity is the amphi-
nating the His tag in the original vector. -arrestins were expressedpathic nature of  helix I, which we propose is released
in E. coli strain BL21 codon plus (Invitrogen) in a 15 liter fermentorwhen the three element interaction is destabilized in the
(Applicon) in 10 liter ECPM1 media [58] at 30C, pH 7.0, and 25%
course of receptor binding [23], as well as the flexible O2 saturation. Cells were induced at 10 O.D. (600 nm) with 100 M
hinges which connect this helix to the body of the N IPTG and harvested by centrifugation after 5 hr. Cell pellets were
domain (Figure 1). This prompted us to hypothesize that flash frozen in liquid N2 and stored at 80C.
The purification was performed at 0C–4C. Cells (100 g) were helix I serves as a reversible membrane anchor, further
resuspended in 300 ml lysis buffer (50 mM NaCl, 20 mM Tris-HClstabilizing the arrestin-receptor complex. Structural
[pH 8.5], 10% glycerol, 1 mM phenylmethylsulfofluoride [PMSF],similarity of the basal state of v- and -arrestin, similar
1 mM benzamidine-HCl, 10 mM ethylenediaminetetraacetic acidfunctional consequences of many homologous muta-
[EDTA], 10 mM ethylene glyco-bis (-aminoethyl ether) N,N,N,N-
tions [13, 16, 33, 53], along with the conservation of key tetraacetic acid [EGTA], 10 mM dithiotreitol [DTT], and seven pellets
residues in other arrestins tempt us to speculate that of Complete protease inhibitor cocktail tablets [Boehringer Mann-
the structure of the active receptor-bound state (sche- heim]) and lysed by passing through a Microfluidizer (Microfluidics
Corp., Newton, MA) 3–4 times at 600 psi. The lysate was clearedmatically depicted in Figure 6) of all arrestin proteins is
by centrifugation at 100,000 g, and the supernatant was combinedalso very similar.
with 40 ml Heparin Sepharose (Pharmacia) resin equilibrated withWhereas all arrestin proteins bind to activated phos-
CB50 (50 mM NaCl, 20 mM Tris-HCl (pH 8.5), 10% glycerol, 0.5 mMphoreceptors, two nonvisual arrestins perform several PMSF, and 2 mM DTT), allowing batch binding for 2 hr under gentle
other functions that visual arrestin apparently does not rotation.
have. These functions fall into two groups. First, both The resin was washed extensively with CB100 (100 mM NaCl, 20
nonvisual arrestins directly interact with various compo- mM Tris-HCl [pH 8.5], 10% glycerol, 0.5 mM PMSF, and 2 mM DTT).
Wild-type -arrestin and -arrestin 1–393 were eluted with 450 Mnents of the trafficking machinery: clathrin [3, 52],
inositolhexakisphosphate (InP6) (Sigma) in CB100. -arrestin 1–382clathrin adaptor AP2 [29], and N-ethylmaleimide-sensi-
was eluted with 3 mM InP6. Fractions containing -arrestin weretive fusion protein (NSF) [6]. Second, nonvisual arrestins
pooled, diluted with CB100, and loaded onto three concatenated 5
serve as scaffolds that participate in the activation of ml Hi-Trap Heparin Sepharose (Pharmacia) columns. The columns
several mitogen-activated protein kinase (MAPK) cas- were washed with CB100 and eluted with a linear gradient from 400
cades [14, 54–57]. In particular, both nonvisual arrestins mM to 1 M NaCl for 10 column volumes. The fractions containing
stimulate the signaling from cRaf-1 via MEK1 to ERK1/2 pure -arrestin were pooled and concentrated to 10 mg/ml in 8
ml collodion membranes (MWCO 25 K, Schleicher and Schuell) with[14, 54, 55]. It appears that arrestins directly interact
frequent mixing and further purified by gel filtration on a Hi-Loadwith cRaf-1 and Erk2, thus facilitating the formation of
16/60 Superdex 75 column (Pharmacia). The final product was con-the cRaf-1, MEK1, Erk2 complex. Similarly, -arrestin2
centrated again to 10 mg/ml for crystallization.
serves as a scaffold for the complex of ASK1, MKK4, Selenomethionine (SeMet)-labeled -arrestin was produced in
and JNK3, in which it directly interacts with ASK1 and methionine auxotrophic B834 in 12 liter defined MOPS-based me-
JNK3 [56, 57]. At physiological expression levels of all dium [59] supplied with 50 mg/L L-SeMet (Sigma). The cells were
grown at 30C and induced at O.D.600 of 0.6 with 50 M IPTG andthe proteins involved, only receptor bound arrestins in-
harvested 5 hr later. Purification was carried out using the sameteract with all these nonreceptor partners, thereby tar-
procedure described above.geting receptors for internalization and linking various
GPCRs to MAPK signaling cascades [14, 54–57]. Recep-
Direct Binding Assaytor binding induces a major conformational change in
In vitro transcription, translation, receptor purification, and phos-arrestins [23, 48, 50], which includes the displacement
phorylation were performed, as described [13]. Translation of all
of the C tail [22, 23]. Interestingly, in sharp contrast to proteins used for direct binding assay yielded a single radiolabeled
visual arrestin [1, 25], the deletion of the -arrestin C band with expected electrophoretic mobility. The stoichiometries
tail promotes its dimerization (Figure 3). In all arrestins, of phosphorylation of rhodopsin and m2 muscarinic cholinergic re-
ceptor (m2 mAChR) used were 2.8 and 3.3 mol phosphate per mol,deletion of the C tail beyond its interactions with strand
respectively. Binding was performed, as described [13]. Briefly, inI yields “preactivated” constitutively active mutants [13,
vitro translated radiolabeled arrestins (50 fmol) were incubated in16, 22, 50, 53], apparently because it mimics C tail dis-
50 mM Tris-HCl (pH 7.5), 0.5 mM MgCl2, 1.5 mM dithiothreitol, andplacement upon receptor binding. Taken together, these
50 mM potassium acetate with 7.5 pmol of phosphorylated light-
data tempt us to speculate that the propensity of active, activated rhodopsin (P-Rh*) or with 100 fmol/assay of carbachol-
receptor bound, nonvisual arrestins to dimerize may play activated phosphorylated P-m2 mAChR in a final volume of 50 l
a role in assembling arrestin-receptor complexes into for 5 min at 37C in room light (rhodopsin) or for 35 min at 30C
(P-m2 mAChR). The samples were then cooled on ice and loadeddimers and/or higher oligomeres prior to internalization.
onto 2 ml sepharose 2B columns equilibrated with 10 mM Tris-Moreover, clathrin, AP2, and NSF, with which nonvisual
HCl (pH 7.4), 100 mM NaCl. Bound arrestin eluted with receptor-arrestins interact in the process, are assembled into
containing membranes in the void volume (between 0.5 and 1.1 ml).multimeric matrices, so that arrestin dimerization may
Nonspecific binding (determined in the presence of 0.3 g lipo-
help arrestin-receptor complexes fit better with the inter- somes; it did not exceed 0.4 fmol/assay) was subtracted. Means 
nalization machinery of the coated pit. It is not clear standard deviation from three experiments performed in duplicate
whether dimerization of nonvisual arrestins plays any are presented.
role in their function as scaffolds for MAPK, but the size
of the complexes containing arrestin and MAPK leaves Crystallization
All three crystal forms were prepared by microbatch crystallizationthis possibility open as well [54, 55].
at 19C under oil; occasionally, microseeding was used to improve
crystal quality. Usually, 3.5 l of protein at a concentration of 5 orExperimental Procedures
7.5 mg/ml in 0.1 M NaCl, 20 mM Tris-HCl (pH 8.5), 1 mM EDTA, 10
mM DTT, and 5% glycerol was mixed 1:1 with the crystallizationExpression and Purification of -Arrestin
solution. Crystals in the trigonal space group were grown from 18%–and Its Truncation Mutants
20% PEG 1500, 0.8 M MgCl2, and 0.1 M Tris-HCl (pH 7.5). CrystalscDNAs encoding bovine -arrestin wild-type, -arrestin 1–393, and
-arrestin 1–382 truncation mutants were cloned in frame in were exposed to increasing concentrations of glycerol and were
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frozen in liquid propane in 30% glycerol, 12% PEG 1500, 0.4 M Received: August 9, 2001
Accepted: August 9, 2001MgCl2, 0.1 M NaCl, 50 mM Tris-HCl (pH 7.5), and 10 mM DTT.
Crystals in the monoclinic space group were grown from 12%–
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